WealthTrust Asset Management LLC Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

WealthTrust Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,385 shares of the company’s stock, valued at approximately $856,000.

Several other hedge funds and other institutional investors have also modified their holdings of TEVA. Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $41,000. Cromwell Holdings LLC increased its stake in Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the period. MAI Capital Management grew its position in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares during the last quarter. Rothschild Investment LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares during the period. Finally, JFS Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares of the company’s stock, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 422,060 shares of company stock worth $12,254,965 over the last ninety days. Corporate insiders own 0.49% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on TEVA shares. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Scotiabank increased their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $33.85 on Friday. The company has a market cap of $38.92 billion, a P/E ratio of 28.21, a P/E/G ratio of 11.30 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock’s 50-day simple moving average is $32.94 and its 200 day simple moving average is $25.68. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the business earned $0.71 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.